| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maria Lindahl, Alcmène Chalazonitis, Erik Palm, Emmi Pakarinen, Tatiana Danilova, Tuan D Pham, Wanda Setlik, Meenakshi Rao, Vootele Võikar, Jatta Huotari, Jaakko Kopra, Jaan-Olle Andressoo, Petteri T Piepponen, Mikko Airavaara, Anne Panhelainen, Michael D Gershon, Mart Saarm. Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice. Neurobiology of disease. vol 134. 2021-01-13. PMID:31783118. |
cerebral dopamine neurotrophic factor (cdnf) is neuroprotective for nigrostriatal dopamine neurons and restores dopaminergic function in animal models of parkinson's disease (pd). |
2021-01-13 |
2023-08-13 |
mouse |
| Carlos Juri, Vasko Kramer, Patrick J Riss, Cristian Soza-Ried, Arlette Haeger, Rossana Pruzzo, Frank Rösch, Horacio Amaral, Pedro Chana-Cueva. [18F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease. Clinical nuclear medicine. vol 46. issue 2. 2021-01-13. PMID:33323728. |
degeneration of dopaminergic, nigrostriatal neurons is the hallmark of parkinson disease (pd), and pet quantification of dopamine transporters is a widely accepted method for differential diagnosis between idiopathic pd and essential tremor. |
2021-01-13 |
2023-08-13 |
Not clear |
| M Angela Cenci, Anders Björklun. Animal models for preclinical Parkinson's research: An update and critical appraisal. Progress in brain research. vol 252. 2021-01-11. PMID:32247366. |
a substantial loss of nigrostriatal dopamine neurons is necessary for the animal to exhibit a hypokinetic motor phenotype responsive to dopaminergic agents, thus resembling clinical pd. |
2021-01-11 |
2023-08-13 |
mouse |
| Hirotaka Sekiguchi, Geoff Pavey, Brian Dea. Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia. NPJ schizophrenia. vol 5. issue 1. 2021-01-10. PMID:31792225. |
we postulated that the dopamine transporter (dat), which regulates intra-synaptic dopamine concentrations by transporting dopamine from the synaptic cleft into the pre-synaptic neuron, could be involved in dopaminergic dysfunction in schizophrenia. |
2021-01-10 |
2023-08-13 |
human |
| Fabin Han, Baoyang H. Stem Cell Therapy for Parkinson's Disease. Advances in experimental medicine and biology. vol 1266. 2021-01-08. PMID:33105493. |
here, we summarize the research advance in experimental and clinical studies to transplant these cells into animal models and clinical patients, and specifically highlight the studies to use hescs /ipscs-derived dopaminergic precursor cells and dopamine neurons for the treatment of pd, at last propose future challenges for developing clinical-grade dopaminergic cells for treating the pd. |
2021-01-08 |
2023-08-13 |
human |
| Ioannis Mantas, Yunting Yang, Clotilde Mannoury-la-Cour, Mark J Millan, Xiaoqun Zhang, Per Svenningsso. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. Neuropharmacology. vol 162. 2021-01-06. PMID:31666199. |
parkinson's disease (pd) is characterized by progressive loss of midbrain dopaminergic neurons and treated with the dopamine precursor, 3,4-dihydroxy-l-phenylalanine (l-dopa). |
2021-01-06 |
2023-08-13 |
mouse |
| A J Robison, Katharine N Thakkar, Vaibhav A Diwadka. Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate. Biological psychiatry. vol 87. issue 3. 2021-01-06. PMID:31733788. |
we then expand on the role of glutamatergic inputs to these dopamine circuits and dopaminergic modulation of critical excitatory pathways with attention given to the role of glutamatergic hippocampal outputs onto nucleus accumbens. |
2021-01-06 |
2023-08-13 |
human |
| Yu-Chia Chen, Diego Baronio, Svetlana Semenova, Shamsiiat Abdurakhmanova, Pertti Panul. Cerebral Dopamine Neurotrophic Factor Regulates Multiple Neuronal Subtypes and Behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 32. 2021-01-04. PMID:32631936. |
cerebral dopamine neurotrophic factor (cdnf) protects dopaminergic neurons against toxic damage in the rodent brain and is in clinical trials to treat parkinson's disease patients. |
2021-01-04 |
2023-08-13 |
zebrafish |
| Fillipe M de Araújo, Lorena Cuenca-Bermejo, Emiliano Fernández-Villalba, Silvia L Costa, Victor Diogenes A Silva, Maria Trinidad Herrer. Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy. Cellular and molecular neurobiology. 2021-01-02. PMID:33387119. |
parkinson's disease (pd) is a neurodegenerative disorder marked primarily by motor symptoms such as rigidity, bradykinesia, postural instability and resting tremor associated with dopaminergic neuronal loss in the substantia nigra pars compacta (snpc) and deficit of dopamine in the basal ganglia. |
2021-01-02 |
2023-08-13 |
Not clear |
| Michael Silkstone, Stefan M Brudzynsk. Dissimilar interaction between dopaminergic and cholinergic systems in the initiation of emission of 50-kHz and 22-kHz vocalizations. Pharmacology, biochemistry, and behavior. vol 188. 2020-12-31. PMID:31655084. |
emission of 50-khz usvs is dependent upon the activation of dopaminergic neurons located within the ventral tegmental area that release dopamine into the medial shell of the nucleus accumbens. |
2020-12-31 |
2023-08-13 |
rat |
| Nikita Katila, Sunil Bhurtel, Pil-Hoon Park, Jin Tae Hong, Dong-Young Cho. Activation of AMPK/aPKCζ/CREB pathway by metformin is associated with upregulation of GDNF and dopamine. Biochemical pharmacology. vol 180. 2020-12-31. PMID:32800853. |
parkinson's disease (pd) is the second most common neurodegenerative disease, which is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to a decrease in striatal dopamine. |
2020-12-31 |
2023-08-13 |
mouse |
| Ali Gheidi, Lora M Cope, Christopher J Fitzpatrick, Benjamin N Froehlich, Rachel Atkinson, Coltrane K Groves, Clair N Barcelo, Jonathan D Morro. Effects of the cannabinoid receptor agonist CP-55,940 on incentive salience attribution. Psychopharmacology. vol 237. issue 9. 2020-12-30. PMID:32494975. |
recent evidence has shown that activity of the endocannabinoid system increases dopaminergic activity in the mesocorticolimbic system, and other studies have shown that sign-tracking behaviors are dependent on dopamine. |
2020-12-30 |
2023-08-13 |
Not clear |
| Daniel S Drew, Kinan Muhammed, Fahd Baig, Mark Kelly, Youssuf Saleh, Nagaraja Sarangmat, David Okai, Michele Hu, Sanjay Manohar, Masud Husai. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. Brain : a journal of neurology. vol 143. issue 8. 2020-12-30. PMID:32761061. |
being off dopaminergic medication overnight did not modulate pupillary reward sensitivity in impulse control disorder patients, whereas in control patients reward sensitivity was significantly reduced when off dopamine. |
2020-12-30 |
2023-08-13 |
human |
| Daniel S Drew, Kinan Muhammed, Fahd Baig, Mark Kelly, Youssuf Saleh, Nagaraja Sarangmat, David Okai, Michele Hu, Sanjay Manohar, Masud Husai. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. Brain : a journal of neurology. vol 143. issue 8. 2020-12-30. PMID:32761061. |
however, there was no difference in reward sensitivity between patient groups when on dopamine medication, suggesting that impulse control disorders may not emerge simply because of a direct effect of dopaminergic drug level on reward sensitivity. |
2020-12-30 |
2023-08-13 |
human |
| Mariana de Souza Aranha Garcia-Gomes, Dennis Albert Zanatto, Orfa Yineth Galvis-Alonso, Jorge Mejia, Ana Tada Fonseca Brasil Antiorio, Pedro Kenzo Yamamoto, Márcia Carolina Millán Olivato, Thaísa Meira Sandini, Jorge Camilo Flório, Ivo Lebrun, Silvia Maria Gomes Massironi, Sandra Regina Alexandre-Ribeiro, Maria Martha Bernardi, Susan Ienne, Tiago Antonio de Souza, Maria Lúcia Zaidan Dagli, Claudia Madalena Cabrera Mor. Behavioral and neurochemical characterization of the spontaneous mutation tremor, a new mouse model of audiogenic seizures. Epilepsy & behavior : E&B. vol 105. 2020-12-29. PMID:32109856. |
regarding to dopaminergic system, neither dopamine (da) and 3,4-dihydroxyphenylacetic acid (dopac) contents nor the turnover rate of da showed statistically significant differences between wt and mutant mice. |
2020-12-29 |
2023-08-13 |
mouse |
| Timothy G Freels, Daniel B K Gabriel, Deranda B Lester, Nicholas W Simo. Risky decision-making predicts dopamine release dynamics in nucleus accumbens shell. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 2. 2020-12-28. PMID:31546248. |
it is well-established that dopaminergic drugs modulate risk-taking; however, little is known about how differences in baseline phasic dopamine signaling drive individual differences in risk preference. |
2020-12-28 |
2023-08-13 |
human |
| Min Lin, Luis M Colon-Perez, Danielle O Sambo, Douglas R Miller, Joseph J Lebowitz, Felix Jimenez-Rondan, Robert J Cousins, Nicole Horenstein, Tolunay Beker Aydemir, Marcelo Febo, Habibeh Khoshboue. Mechanism of Manganese Dysregulation of Dopamine Neuronal Activity. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 40. issue 30. 2020-12-25. PMID:32576620. |
it is unknown, however, how manganese accumulates in dopaminergic brain regions or how it regulates the activity of dopamine neurons. |
2020-12-25 |
2023-08-13 |
Not clear |
| Qi Mao, Wang-Zhi Qin, Ao Zhang, Na Y. Recent advances in dopaminergic strategies for the treatment of Parkinson's disease. Acta pharmacologica Sinica. vol 41. issue 4. 2020-12-21. PMID:32112042. |
based on the loss of dopamine or dopaminergic dysfunction in pd patients, most of the current therapies focus on symptomatic relief to improve patient quality of life. |
2020-12-21 |
2023-08-13 |
Not clear |
| Qi Mao, Wang-Zhi Qin, Ao Zhang, Na Y. Recent advances in dopaminergic strategies for the treatment of Parkinson's disease. Acta pharmacologica Sinica. vol 41. issue 4. 2020-12-21. PMID:32112042. |
as dopamine replacement treatment remains the most effective symptomatic pharmacotherapy for pd, herein we provide an overview of the current pharmacotherapies, summarize the clinical development status of novel dopaminergic agents, and highlight the challenge and opportunity of emerging preclinical dopaminergic approaches aimed at managing the features and progression of pd. |
2020-12-21 |
2023-08-13 |
Not clear |
| Changliang Li. Targeting the cholinergic system in Parkinson's disease. Acta pharmacologica Sinica. vol 41. issue 4. 2020-12-21. PMID:32132659. |
in addition to dopaminergic innervation, giant aspiny cholinergic interneurons (chis) within the striatum have long been recognized as a critical node for balancing dopamine signaling and regulating movement. |
2020-12-21 |
2023-08-13 |
Not clear |